Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 5/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.48 |
| ▸ | HTR5A | P47898 | 1/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | APOB | P04114 | 1/20 | 0.40 |
| ▸ | MTTP | P55157 | 1/20 | 0.40 |
| ▸ | SMO | Q99835 | 3/20 | 0.40 |
| ▸ | VCP | P55072 | 3/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3338259 | 0.93 | SLC2A1 (0.49) | SLC2A1HDAC1HTR5APRMT5APOB | |
| SCHEMBL1787991 | 0.90 | HDAC1 (0.47) | SLC2A1HDAC1HTR5APRMT5VCP | |
| Trifluoroacetic Acid SCHEMBL3340019 | 0.85 | SLC2A1 (0.41) | SLC2A1HDAC1HTR5AVCPMEN1 | |
| Trifluoroacetic Acid SCHEMBL3337454 | 0.83 | SLC2A1 (0.55) | SLC2A1HDAC1HTR5APRMT5APOB | |
| Trifluoroacetic Acid SCHEMBL3340384 | 0.82 | SLC2A1 (0.54) | SLC2A1HDAC1HTR5APRMT5APOB | |
| SCHEMBL1789964 | 0.82 | NISCH (0.44) | SLC2A1HDAC1HTR5APRMT5FYN | |
| Trifluoroacetic Acid SCHEMBL16195088 | 0.81 | SLC2A1 (0.53) | SLC2A1HDAC1HTR5APRMT5APOB | |
| Trifluoroacetic Acid SCHEMBL1790201 | 0.81 | SLC2A1 (0.58) | SLC2A1HDAC1HTR5APRMT5APOB | |
| SCHEMBL3342454 | 0.80 | VCP (0.36) | SLC2A1HDAC1PRMT5VCP | |
| Trifluoroacetic Acid SCHEMBL3050323 | 0.79 | SLC2A1 (0.51) | SLC2A1HDAC1HTR5APRMT5APOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRD1, OPRK1 | SLC2A1 2287/4885HDAC1 1478/4885HTR5A 281/4885 |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | SLC2A1 4173/4885HDAC1 2440/4885HTR5A 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.